Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04683653 · ClinicalTrials.gov registry record · Phase 1
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
A Phase 1 study of Endometrial Cancer, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 5
- Study locations
NCT04683653 is a Phase 1 study of Endometrial Cancer that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 100 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04683653, a Phase 1 study of Endometrial Cancer, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).
Conditions Studied
Interventions
- RADIATION Hypofractionated Radiation
- OTHER Clinical Follow-Up and Assessments
Study Locations (5)
Illinois
- University of Illinois at Chicago (UIC) - Chicago
- University of Chicago - Chicago
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2027-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04683653
The ClinicalTrials.gov registry entry for NCT04683653 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (81% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Hypofractionated Radiation is the first listed.
NCT04683653 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT04683653 about?
NCT04683653 is a clinical study titled "Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer". This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in ...
What is the current status of trial NCT04683653?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2021-01-15. Estimated completion is 2027-05-22.
What conditions does trial NCT04683653 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT04683653?
The interventions under investigation include: Hypofractionated Radiation (RADIATION), Clinical Follow-Up and Assessments (OTHER).
Who is sponsoring clinical trial NCT04683653?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04683653 being conducted?
This trial has 5 study locations across Georgia, Illinois, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.